Siegel, R, Ma, J, Zou, Z, Jemal, A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9–29.
Ferlay, J, Soerjomataram, I, Ervik, M, Dikshit, R, Eser, S, Mathers, C, Rebelo, M, Parkin, DM, Forman, D, Bray, F. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon: IARC; 2013. Available at: http://globocan.iarc.fr.
Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E, Forman, D. Global cancer statistics. CA Cancer J Clin 2011, 61:69–90.
Sorlie, T, Perou, CM, Tibshirani, R, Aas, T, Geisler, S, Johnsen, H, Hastie, T, Eisen, MB, van de Rijn, M, Jeffrey, SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869–10874.
Nielsen, TO, Hsu, FD, Jensen, K, Cheang, M, Karaca, G, Hu, Z, Hernandez‐Boussard, T, Livasy, C, Cowan, D, Dressler, L, et al. Immunohistochemical and clinical characterization of the basal‐like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367–5374.
Prat, A, Adamo, B, Cheang, MC, Anders, CK, Carey, LA, Perou, CM. Molecular characterization of basal‐like and non‐basal‐like triple‐negative breast cancer. Oncologist 2013, 18:123–133.
Baselga, J, Cortes, J, Kim, SB, Im, SA, Hegg, R, Im, YH, Roman, L, Pedrini, JL, Pienkowski, T, Knott, A, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109–119.
Early Breast Cancer Trialists` Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15‐year survival: an overview of the randomised trials. Lancet 2005, 365:1687–1717.
Carey, LA, Perou, CM, Livasy, CA, Dressler, LG, Cowan, D, Conway, K, Karaca, G, Troester, MA, Tse, CK, Edmiston, S, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492–2502.
Bauer, KR, Brown, M, Cress, RD, Parise, CA, Caggiano, V. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype: a population‐based study from the California Cancer Registry. Cancer 2007, 109:1721–1728.
Foulkes, WD, Stefansson, IM, Chappuis, PO, Begin, LR, Goffin, JR, Wong, N, Trudel, M, Akslen, LA. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95:1482–1485.
Dogan, BE, Gonzalez‐Angulo, AM, Gilcrease, M, Dryden, MJ, Yang, WT. Multimodality imaging of triple receptor‐negative tumors with mammography, ultrasound, and MRI. AJR Am J Roentgenol 2010, 194:1160–1166.
Oakman, C, Viale, G, Di Leo, A. Management of triple negative breast cancer. Breast 2010, 19:312–321.
Dent, R, Trudeau, M, Pritchard, KI, Hanna, WM, Kahn, HK, Sawka, CA, Lickley, LA, Rawlinson, E, Sun, P, Narod, SA. Triple‐negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429–4434.
Liedtke, C, Mazouni, C, Hess, KR, Andre, F, Tordai, A, Mejia, JA, Symmans, WF, Gonzalez‐Angulo, AM, Hennessy, B, Green, M, et al. Response to neoadjuvant therapy and long‐term survival in patients with triple‐negative breast cancer. J Clin Oncol 2008, 26:1275–1281.
Dent, R, Hanna, WM, Trudeau, M, Rawlinson, E, Sun, P, Narod, SA. Pattern of metastatic spread in triple‐negative breast cancer. Breast Cancer Res Treat 2009, 115:423–428.
Haffty, BG, Yang, Q, Reiss, M, Kearney, T, Higgins, SA, Weidhaas, J, Harris, L, Hait, W, Toppmeyer, D. Locoregional relapse and distant metastasis in conservatively managed triple negative early‐stage breast cancer. J Clin Oncol 2006, 24:5652–5657.
Isakoff, SJ. Triple‐negative breast cancer: role of specific chemotherapy agents. Cancer J 2010, 16:53–61.
Adkins, FC, Gonzalez‐Angulo, AM, Lei, X, Hernandez‐Aya, LF, Mittendorf, EA, Litton, JK, Wagner, J, Hunt, KK, Woodward, WA, Meric‐Bernstam, F. Triple‐negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol 2011, 18:3164–3173.
Li, X, Lewis, MT, Huang, J, Gutierrez, C, Osborne, CK, Wu, MF, Hilsenbeck, SG, Pavlick, A, Zhang, X, Chamness, GC, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672–679.
Guarneri, V, Broglio, K, Kau, SW, Cristofanilli, M, Buzdar, AU, Valero, V, Buchholz, T, Meric, F, Middleton, L, Hortobagyi, GN, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006, 24:1037–1044.
Prat, A, Perou, CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011, 5:5–23.
Lehmann, BD, Bauer, JA, Chen, X, Sanders, ME, Chakravarthy, AB, Shyr, Y, Pietenpol, JA. Identification of human triple‐negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750–2767.
Masuda, H, Baggerly, KA, Wang, Y, Zhang, Y, Gonzalez‐Angulo, AM, Meric‐Bernstam, F, Valero, V, Lehmann, BD, Pietenpol, JA, Hortobagyi, GN, et al. Differential response to neoadjuvant chemotherapy among 7 triple‐negative breast cancer molecular subtypes. Clin Cancer Res 2013, 19:5533–5540.
Prat, A, Lluch, A, Albanell, J, Barry, WT, Fan, C, Chacon, JI, Parker, JS, Calvo, L, Plazaola, A, Arcusa, A, et al. Predicting response and survival in chemotherapy‐treated triple‐negative breast cancer. Br J Cancer 2014, 111:1532–1541.
Kennedy, RD, Quinn, JE, Mullan, PB, Johnston, PG, Harkin, DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004, 96:1659–1668.
Loi, S, Pommey, S, Haibe‐Kains, B, Beavis, PA, Darcy, PK, Smyth, MJ, Stagg, J. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci USA 2013, 110:11091–11096.
Chekhun, VF, Zhylchuk, VE, Lukyanova, NY, Vorontsova, AL, Kudryavets, YI. Expression of drug resistance proteins in triple‐receptor‐negative tumors as the basis of individualized therapy of the breast cancer patients. Exp Oncol 2009, 31:123–124.
Soma, CE, Dubernet, C, Bentolila, D, Benita, S, Couvreur, P. Reversion of multidrug resistance by co‐encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 2000, 21:1–7.
Kobayashi, H, Watanabe, R, Choyke, PL. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics 2013, 4:81–89.
Maeda, H, Wu, J, Sawa, T, Matsumura, Y, Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271–284.
Yang, WT, Dryden, M, Broglio, K, Gilcrease, M, Dawood, S, Dempsey, PJ, Valero, V, Hortobagyi, G, Atchley, D, Arun, B. Mammographic features of triple receptor‐negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 2008, 111:405–410.
de Kruijf, EM, van Nes, JG, van de Velde, CJ, Putter, H, Smit, VT, Liefers, GJ, Kuppen, PJ, Tollenaar, RA, Mesker, WE. Tumor‐stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple‐negative carcinoma patients. Breast Cancer Res Treat 2011, 125:687–696.
Jain, RK, Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653–664.
Sykes, EA, Chen, J, Zheng, G, Chan, WC. Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano 2014, 8:5696–5706.
Bertrand, N, Wu, J, Xu, X, Kamaly, N, Farokhzad, OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014, 66:2–25.
Mazar, AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res 2008, 14:5649–5655.
Nielsen, BS, Rank, F, Illemann, M, Lund, LR, Dano, K. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int J Cancer 2007, 120:2086–2095.
Pyke, C, Graem, N, Ralfkiaer, E, Ronne, E, Hoyer‐Hansen, G, Brunner, N, Dano, K. Receptor for urokinase is present in tumor‐associated macrophages in ductal breast carcinoma. Cancer Res 1993, 53:1911–1915.
Han, B, Nakamura, M, Mori, I, Nakamura, Y, Kakudo, K. Urokinase‐type plasminogen activator system and breast cancer (Review). Oncol Rep 2005, 14:105–112.
Yang, L, Peng, XH, Wang, YA, Wang, X, Cao, Z, Ni, C, Karna, P, Zhang, X, Wood, WC, Gao, X, et al. Receptor‐targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res 2009, 15:4722–4732.
Yang, L, Sajja, HK, Cao, Z, Qian, W, Bender, L, Marcus, AI, Lipowska, M, Wood, WC, Wang, YA. uPAR‐targeted optical imaging contrasts as theranostic agents for tumor margin detection. Theranostics 2013, 4:106–118.
LeBeau, AM, Duriseti, S, Murphy, ST, Pepin, F, Hann, B, Gray, JW, VanBrocklin, HF, Craik, CS. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res 2013, 73:2070–2081.
Meijer‐van Gelder, ME, Look, MP, Peters, HA, Schmitt, M, Brunner, N, Harbeck, N, Klijn, JG, Foekens, JA. Urokinase‐type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res 2004, 64:4563–4568.
LeBeau, AM, Sevillano, N, King, ML, Duriseti, S, Murphy, ST, Craik, CS, Murphy, LL, VanBrocklin, HF. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance. Theranostics 2014, 4:267–279.
Tan, DS, Marchio, C, Jones, RL, Savage, K, Smith, IE, Dowsett, M, Reis‐Filho, JS. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline‐treated patients. Breast Cancer Res Treat 2008, 111:27–44.
Viale, G, Rotmensz, N, Maisonneuve, P, Bottiglieri, L, Montagna, E, Luini, A, Veronesi, P, Intra, M, Torrisi, R, Cardillo, A, et al. Invasive ductal carcinoma of the breast with the “triple‐negative” phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009, 116:317–328.
Masuda, H, Zhang, D, Bartholomeusz, C, Doihara, H, Hortobagyi, GN, Ueno, NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 2012, 136:331–345.
Baselga, J, Gomez, P, Greil, R, Braga, S, Climent, MA, Wardley, AM, Kaufman, B, Stemmer, SM, Pego, A, Chan, A, et al. Randomized phase II study of the anti‐epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple‐negative breast cancer. J Clin Oncol 2013, 31:2586–2592.
Dickler, MN, Cobleigh, MA, Miller, KD, Klein, PM, Winer, EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2009, 115:115–121.
Filmus, J, Trent, JM, Pollak, MN, Buick, RN. Epidermal growth factor receptor gene‐amplified MDA‐468 breast cancer cell line and its nonamplified variants. Mol Cell Biol 1987, 7:251–257.
Fitzpatrick, SL, LaChance, MP, Schultz, GS. Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture. Cancer Res 1984, 44:3442–3447.
Pollak, MN, Schernhammer, ES, Hankinson, SE. Insulin‐like growth factors and neoplasia. Nat Rev Cancer 2004, 4:505–518.
Resnik, JL, Reichart, DB, Huey, K, Webster, NJ, Seely, BL. Elevated insulin‐like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998, 58:1159–1164.
Yerushalmi, R, Gelmon, KA, Leung, S, Gao, D, Cheang, M, Pollak, M, Turashvili, G, Gilks, BC, Kennecke, H. Insulin‐like growth factor receptor (IGF‐1R) in breast cancer subtypes. Breast Cancer Res Treat 2012, 132:131–142.
Law, JH, Habibi, G, Hu, K, Masoudi, H, Wang, MY, Stratford, AL, Park, E, Gee, JM, Finlay, P, Jones, HE, et al. Phosphorylated insulin‐like growth factor‐i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008, 68:10238–10246.
Litzenburger, BC, Creighton, CJ, Tsimelzon, A, Chan, BT, Hilsenbeck, SG, Wang, T, Carboni, JM, Gottardis, MM, Huang, F, Chang, JC, et al. High IGF‐IR activity in triple‐negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti‐IGF‐IR therapy. Clin Cancer Res 2011, 17:2314–2327.
Balko, JM, Giltnane, JM, Wang, K, Schwarz, LJ, Young, CD, Cook, RS, Owens, P, Sanders, ME, Kuba, MG, Sanchez, V, et al. Molecular profiling of the residual disease of triple‐negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 2014, 4:232–245.
Yang, L, Wu, X, Wang, Y, Zhang, K, Wu, J, Yuan, YC, Deng, X, Chen, L, Kim, CC, Lau, S, et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 2011, 30:4437–4446.
Bilir, B, Kucuk, O, Moreno, CS. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple‐negative breast cancer cells. J Transl Med 2013, 11:280.
Dey, N, Barwick, BG, Moreno, CS, Ordanic‐Kodani, M, Chen, Z, Oprea‐Ilies, G, Tang, W, Catzavelos, C, Kerstann, KF, Sledge, GW Jr, et al. Wnt signaling in triple negative breast cancer is associated with metastasis. BMC Cancer 2013, 13:537.
Yang, L, Perez, AA, Fujie, S, Warden, C, Li, J, Wang, Y, Yung, B, Chen, YR, Liu, X, Zhang, H, et al. Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 2014, 14:124.
Willnow, TE, Nykjaer, A, Herz, J. Lipoprotein receptors: new roles for ancient proteins. Nat Cell Biol 1999, 1:E157–E162.
Siroy, A, Abdul‐Karim, FW, Miedler, J, Fong, N, Fu, P, Gilmore, H, Baar, J. MUC1 is expressed at high frequency in early‐stage basal‐like triple‐negative breast cancer. Hum Pathol 2013, 44:2159–2166.
Ren, J, Agata, N, Chen, D, Li, Y, Yu, WH, Huang, L, Raina, D, Chen, W, Kharbanda, S, Kufe, D. Human MUC1 carcinoma‐associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004, 5:163–175.
Kufe, DW. MUC1‐C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 2013, 32:1073–1081.
Raina, D, Ahmad, R, Joshi, MD, Yin, L, Wu, Z, Kawano, T, Vasir, B, Avigan, D, Kharbanda, S, Kufe, D. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009, 69:5133–5141.
Alam, M, Rajabi, H, Ahmad, R, Jin, C, Kufe, D. Targeting the MUC1‐C oncoprotein inhibits self‐renewal capacity of breast cancer cells. Oncotarget 2014, 5:2622–2634.
Tammi, RH, Kultti, A, Kosma, VM, Pirinen, R, Auvinen, P, Tammi, MI. Hyaluronan in human tumors: pathobiological and prognostic messages from cell‐associated and stromal hyaluronan. Semin Cancer Biol 2008, 18:288–295.
Auvinen, P, Rilla, K, Tumelius, R, Tammi, M, Sironen, R, Soini, Y, Kosma, VM, Mannermaa, A, Viikari, J, Tammi, R. Hyaluronan synthases (HAS1‐3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival. Breast Cancer Res Treat 2014, 143:277–286.
Idowu, MO, Kmieciak, M, Dumur, C, Burton, RS, Grimes, MM, Powers, CN, Manjili, MH. CD44(+)/CD24(−/low) cancer stem/progenitor cells are more abundant in triple‐negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 2012, 43:364–373.
Culty, M, Nguyen, HA, Underhill, CB. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol 1992, 116:1055–1062.
Misra, S, Heldin, P, Hascall, VC, Karamanos, NK, Skandalis, SS, Markwald, RR, Ghatak, S. Hyaluronan‐CD44 interactions as potential targets for cancer therapy. FEBS J 2011, 278:1429–1443.
O`Shannessy, DJ, Somers, EB, Maltzman, J, Smale, R, Fu, YS. Folate receptor α (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springerplus 2012, 1:22.
Leamon, CP, Reddy, JA. Folate‐targeted chemotherapy. Adv Drug Deliv Rev 2004, 56:1127–1141.
Zhang, Z, Wang, J, Tacha, DE, Li, P, Bremer, RE, Chen, H, Wei, B, Xiao, X, Da, J, Skinner, K, et al. Folate receptor α associated with triple‐negative breast cancer and poor prognosis. Arch Pathol Lab Med 2014, 138:890–895.
Leamon, CP, Low, PS. Folate‐mediated targeting: from diagnostics to drug and gene delivery. Drug Discov Today 2001, 6:44–51.
Chu, QD, Panu, L, Holm, NT, Li, BD, Johnson, LW, Zhang, S. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. J Surg Res 2010, 159:689–695.
Chen, HW, Du, CW, Wei, XL, Khoo, US, Zhang, GJ. Cytoplasmic CXCR4 high‐expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple‐negative breast cancer. Curr Mol Med 2013, 13:410–416.
Orimo, A, Gupta, PB, Sgroi, DC, Arenzana‐Seisdedos, F, Delaunay, T, Naeem, R, Carey, VJ, Richardson, AL, Weinberg, RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF‐1/CXCL12 secretion. Cell 2005, 121:335–348.
Kojima, Y, Acar, A, Eaton, EN, Mellody, KT, Scheel, C, Ben‐Porath, I, Onder, TT, Wang, ZC, Richardson, AL, Weinberg, RA, et al. Autocrine TGF‐β and stromal cell‐derived factor‐1 (SDF‐1) signaling drives the evolution of tumor‐promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 2010, 107:20009–20014.
Liang, Z, Zhan, W, Zhu, A, Yoon, Y, Lin, S, Sasaki, M, Klapproth, JM, Yang, H, Grossniklaus, HE, Xu, J, et al. Development of a unique small molecule modulator of CXCR4. PLoS One 2012, 7:e34038.
Sajja, HK, East, MP, Mao, H, Wang, YA, Nie, S, Yang, L. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol 2009, 6:43–51.
O`Brien, ME, Wigler, N, Inbar, M, Rosso, R, Grischke, E, Santoro, A, Catane, R, Kieback, DG, Tomczak, P, Ackland, SP, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first‐line treatment of metastatic breast cancer. Ann Oncol 2004, 15:440–449.
Huober, J, Fett, W, Nusch, A, Neise, M, Schmidt, M, Wischnik, A, Gerhardt, S, Goehler, T, Luck, HJ, Rost, A. A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. BMC Cancer 2010, 10:2.
Gradishar, WJ. Albumin‐bound paclitaxel: a next‐generation taxane. Expert Opin Pharmacother 2006, 7:1041–1053.
Yamamoto, Y, Kawano, I, Iwase, H. Nab‐paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther 2011, 4:123–136.
Miele, E, Spinelli, GP, Miele, E, Tomao, F, Tomao, S. Albumin‐bound formulation of paclitaxel (Abraxane ABI‐007) in the treatment of breast cancer. Int J Nanomedicine 2009, 4:99–105.
Allen, TM, Cullis, PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013, 65:36–48.
Ahn, RW, Chen, F, Chen, H, Stern, ST, Clogston, JD, Patri, AK, Raja, MR, Swindell, EP, Parimi, V, Cryns, VL, et al. A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res 2010, 16:3607–3617.
Lee, ES, Gao, Z, Bae, YH. Recent progress in tumor pH targeting nanotechnology. J Control Release 2008, 132:164–170.
Awada, A, Bondarenko, IN, Bonneterre, J, Nowara, E, Ferrero, JM, Bakshi, AV, Wilke, C, Piccart, M, CT4002 Study Group. A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple‐negative breast cancer (TNBC). Ann Oncol 2014, 25:824–831.
Mamot, C, Ritschard, R, Wicki, A, Kung, W, Schuller, J, Herrmann, R, Rochlitz, C. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR‐overexpressing tumor cells. J Drug Target 2012, 20:422–432.
Guo, P, You, JO, Yang, J, Jia, D, Moses, MA, Auguste, DT. Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH‐triggered siRNA delivery and chemokine axis blockade. Mol Pharm 2014, 11:755–765.
Gao, ZG, Tian, L, Hu, J, Park, IS, Bae, YH. Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles. J Control Release 2011, 152:84–89.
Luk, BT, Fang, RH, Zhang, L. Lipid‐ and polymer‐based nanostructures for cancer theranostics. Theranostics 2012, 2:1117–1126.
Dai, W, Yang, F, Ma, L, Fan, Y, He, B, He, Q, Wang, X, Zhang, H, Zhang, Q. Combined mTOR inhibitor rapamycin and doxorubicin‐loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple‐negative breast cancer. Biomaterials 2014, 35:5347–5358.
Li, S, Goins, B, Hrycushko, BA, Phillips, WT, Bao, A. Feasibility of eradication of breast cancer cells remaining in postlumpectomy cavity and draining lymph nodes following intracavitary injection of radioactive immunoliposomes. Mol Pharm 2012, 9:2513–2522.
Sepehri, N, Rouhani, H, Tavassolian, F, Montazeri, H, Khoshayand, MR, Ghahremani, MH, Ostad, SN, Atyabi, F, Dinarvand, R. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan. Int J Pharm 2014, 471:485–497.
Schluep, T, Hwang, J, Cheng, J, Heidel, JD, Bartlett, DW, Hollister, B, Davis, ME. Preclinical efficacy of the camptothecin‐polymer conjugate IT‐101 in multiple cancer models. Clin Cancer Res 2006, 12:1606–1614.
Young, C, Schluep, T, Hwang, J, Eliasof, S. CRLX101 (formerly IT‐101)—a novel nanopharmaceutical of camptothecin in clinical development. Curr Bioact Compd 2011, 7:8–14.
Li, Y, Jin, M, Shao, S, Huang, W, Yang, F, Chen, W, Zhang, S, Xia, G, Gao, Z. Small‐sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically‐relevant 4T1 mouse breast cancer model. BMC Cancer 2014, 14:329.
Johnstone, TC, Kulak, N, Pridgen, EM, Farokhzad, OC, Langer, R, Lippard, SJ. Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties. ACS Nano 2013, 7:5675–5683.
Lee, SM, Ahn, RW, Chen, F, Fought, AJ, O`Halloran, TV, Cryns, VL, Nguyen, ST. Biological evaluation of pH‐responsive polymer‐caged nanobins for breast cancer therapy. ACS Nano 2010, 4:4971–4978.
Deng, X, Cao, M, Zhang, J, Hu, K, Yin, Z, Zhou, Z, Xiao, X, Yang, Y, Sheng, W, Wu, Y, et al. Hyaluronic acid‐chitosan nanoparticles for co‐delivery of MiR‐34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials 2014, 35:4333–4344.
Swaminathan, SK, Roger, E, Toti, U, Niu, L, Ohlfest, JR, Panyam, J. CD133‐targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release 2013, 171:280–287.
Zhou, W, Zhou, Y, Wu, J, Liu, Z, Zhao, H, Liu, J, Ding, J. Aptamer‐nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells. J Drug Target 2014, 22:57–66.
Kulhari, H, Pooja, D, Shrivastava, S, Naidu, VGM, Sistla, R. Peptide conjugated polymeric nanoparticles as a carrier for targeted delivery of docetaxel. Colloids Surf B Biointerfaces 2014, 117:166–173.
Milane, L, Duan, Z, Amiji, M. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR‐targeted nanoparticles for the treatment of multi‐drug resistant cancer. PLoS One 2011, 6:e24075.
Milane, L, Duan, ZF, Amiji, M. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR‐targeted nanoparticles in an orthotopic animal model of multi‐drug resistant breast cancer. Nanomedicine 2011, 7:435–444.
Dreaden, EC, Morton, SW, Shopsowitz, KE, Choi, JH, Deng, ZJ, Cho, NJ, Hammond, PT. Bimodal tumor‐targeting from microenvironment responsive hyaluronan layer‐by‐layer (LbL) nanoparticles. ACS Nano 2014, 8:8374–8382.
Huang, J, Zhang, H, Yu, Y, Chen, Y, Wang, D, Zhang, G, Zhou, G, Liu, J, Sun, Z, Sun, D, et al. Biodegradable self‐assembled nanoparticles of poly (D,L‐lactide‐co‐glycolide)/hyaluronic acid block copolymers for target delivery of docetaxel to breast cancer. Biomaterials 2014, 35:550–566.
Geng, J, Sun, C, Liu, J, Liao, LD, Yuan, Y, Thakor, N, Wang, J, Liu, B. Biocompatible conjugated polymer nanoparticles for efficient photothermal tumor therapy. Small (Epub ahead of print; 2014 Nov 3). doi:10.1002/smll.201402092.
Guo, J, Hong, H, Chen, G, Shi, S, Zheng, Q, Zhang, Y, Theuer, CP, Barnhart, TE, Cai, W, Gong, S. Image‐guided and tumor‐targeted drug delivery with radiolabeled unimolecular micelles. Biomaterials 2013, 34:8323–8332.
Liu, Z, Chen, K, Davis, C, Sherlock, S, Cao, Q, Chen, X, Dai, H. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 2008, 68:6652–6660.
Robinson, JT, Welsher, K, Tabakman, SM, Sherlock, SP, Wang, H, Luong, R, Dai, H. High performance in vivo near‐IR (%3E1 mum) imaging and photothermal cancer therapy with carbon nanotubes. Nano Res 2010, 3:779–793.
Liu, Z, Tabakman, S, Sherlock, S, Li, X, Chen, Z, Jiang, K, Fan, S, Dai, H. Multiplexed five‐color molecular imaging of cancer cells and tumor tissues with carbon nanotube Raman tags in the near‐infrared. Nano Res 2010, 3:222–233.
De la Zerda, A, Zavaleta, C, Keren, S, Vaithilingam, S, Bodapati, S, Liu, Z, Levi, J, Smith, BR, Ma, TJ, Oralkan, O, et al. Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol 2008, 3:557–562.
Ayala‐Orozco, C, Urban, C, Bishnoi, S, Urban, A, Charron, H, Mitchell, T, Shea, M, Nanda, S, Schiff, R, Halas, N, et al. Sub‐100 nm gold nanomatryoshkas improve photo‐thermal therapy efficacy in large and highly aggressive triple negative breast tumors. J Control Release 2014, 191:90–97.
Wang, D, Xu, Z, Yu, H, Chen, X, Feng, B, Cui, Z, Lin, B, Yin, Q, Zhang, Z, Chen, C, et al. Treatment of metastatic breast cancer by combination of chemotherapy and photothermal ablation using doxorubicin‐loaded DNA wrapped gold nanorods. Biomaterials 2014, 35:8374–8384.
You, J, Zhang, G, Li, C. Exceptionally high payload of doxorubicin in hollow gold nanospheres for near‐infrared light‐triggered drug release. ACS Nano 2010, 4:1033–1041.
Bulte, JW, Kraitchman, DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004, 17:484–499.
Schultz, JF, Bell, JD, Goldstein, RM, Kuhn, JA, McCarty, TM. Hepatic tumor imaging using iron oxide MRI: comparison with computed tomography, clinical impact, and cost analysis. Ann Surg Oncol 1999, 6:691–698.
Harisinghani, MG, Barentsz, J, Hahn, PF, Deserno, WM, Tabatabaei, S, van de Kaa, CH, de la Rosette, J, Weissleder, R. Noninvasive detection of clinically occult lymph‐node metastases in prostate cancer. N Engl J Med 2003, 348:2491–2499.
McCarthy, JR, Weissleder, R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 2008, 60:1241–1251.
Medarova, Z, Rashkovetsky, L, Pantazopoulos, P, Moore, A. Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging. Cancer Res 2009, 69:1182–1189.
Yang, L, Cao, Z, Sajja, HK, Mao, H, Wang, L, Geng, H, Xu, H, Jiang, T, Wood, WC, Nie, S, et al. Development of receptor targeted magnetic iron oxide nanoparticles for efficient drug delivery and tumor imaging. J Biomed Nanotechnol 2008, 4:439–449.
Wang, L, Zhong, X, Qian, W, Huang, J, Cao, Z, Yu, Q, Lipowska, M, Lin, R, Wang, A, Yang, L, et al. Ultrashort echo time (UTE) imaging of receptor targeted magnetic iron oxide nanoparticles in mouse tumor models. J Magn Reson Imaging 2014, 40:1071–1081.
He, Y, Zhang, L, Zhu, D, Song, C. Design of multifunctional magnetic iron oxide nanoparticles/mitoxantrone‐loaded liposomes for both magnetic resonance imaging and targeted cancer therapy. Int J Nanomedicine 2014, 9:4055–4066.
Xi, L, Zhou, G, Gao, N, Yang, L, Gonzalo, D, Hughes, S, Jiang, H. Photoacoustic and fluorescence image‐guided surgery using a multifunctional targeted nanoprobe. Ann Surg Oncol 2014, 21:1602–1609.
Cao, Z, Lee, GY, Wang, A, Sajja, HK, Wang, L, Long, R, Barwick, BG, Leyland‐Jones, BR, Wood, WC, Nie, S, et al. Theranostic nanoparticles for targeted therapy of triple negative breast cancer and for monitoring therapeutic response by MRI. Cancer Res 2010, 70:5482.
Guo, P, Huang, J, Wang, L, Jia, D, Yang, J, Dillon, DA, Zurakowski, D, Mao, H, Moses, MA, Auguste, DT. ICAM‐1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci USA 2014, 111:14710–14715.
https://clinicaltrials.gov/ct2/show/NCT01770353. (Accessed January 3, 2015).